Posts

Collegium Pharmaceutical Acquires ADHD Drug AZSTARYS from Corium for $650 Million

on
Collegium Pharmaceutical has agreed to acquire AZSTARYS from privately held Corium Therapeutics Holdings for $650 million in cash at closing 2 3 The deal includes $135 million in potential milestone payments, bringing the total value to up to $785 million 2 5 AZSTARYS is an ADHD medication being acquired as part of Collegium's strategy to expand its product portfolio 2 The acquisition is expected to drive additional topline revenue growth for Collegium in 2026 6 Sources: 2. https://www.fiercepharma.com/pharma/collegium-ponies-650m-gain-adhd-drug-azstarys-corium 3. https://www.gurufocus.com/news/8726647/collegium-pharmaceutical-coll-to-acquire-azstarys-for-650-million 5. https://www.tradingview.com/news/reuters.com,2026:newsml_L4N4071DC:0-collegium-pharmaceutical-to-acquire-corium-s-adhd-drug-for-up-to-785-million/ 6. https://www.sec.gov/Archives/edgar/data/1267565/000110465926001953/tm262493d1_ex99-1.htm

Pfizer's Talzenna Approved for Earlier Use in Prostate Cancer Following Phase 3 Trial Success

on

AstraZeneca Announces Cell Therapy Manufacturing Hub and R&D Center in Shanghai

on

Lilly's Triple-G Retatrutide Achieves 16.8% Weight Loss and A1C Reductions in Phase 3 Type 2 Diabetes Trial

on

Stoke Therapeutics' Zorevunersen Shows Promise in Restoring Development in Dravet Syndrome Beyond Seizure Reduction

on

Sanofi Inks $2.56 Billion Autoimmune Bispecific Deal with Earendil Labs

on

Aspen Neuroscience's Personalized Parkinson's Therapy Shows Early Promise with 12-Month Data

on

Crossbow Therapeutics Raises $77M Series B to Advance T-Bolt T-Cell Engager Therapies

on

Excalipoint Therapeutics Launches with $68.7M to Advance T-Cell Engagers in Shanghai

on

FDA Policy on RMAT Designations for Therapies on Clinical Hold Remains Unchanged

on

IsomAb Appoints Dr. Philip Brainin as Chief Executive Officer

on

Court Restores Vaccine Status Quo Amid Warnings of Ongoing Legal Battle

on

ClearNote Health Appoints Jeffrey Venstrom, MD, as Chief Medical Officer and Expands Leadership Team

on